Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indevus/Pliva Sanctura clears FDA

Executive Summary

Indevus/Pliva's Sanctura (trospium) clears FDA May 28 for treatment of overactive bladder. Product will be launched in third quarter. Sanctura is first new molecular entity approved for overactive bladder since Pharmacia's Detrol (tolterodine) in 1998 [Editor's Note: More coverage of the Sanctura approval appears in 1"The Pink Sheet" DAILY. Visit our website,, to sign up for a free trial.]....

You may also be interested in...

Indevus/Pliva Sanctura Will Enter Overactive Bladder Market In Third Quarter

Indevus/Pliva's Sanctura will enter the overactive bladder market during the third quarter

Faster, Better? Fujitsu, Polarisqb 'Quantum-Inspired' Tech Speeds Discovery

Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.

Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts